Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2003-06-06
2004-09-28
Aulakh, Charanjit S. (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S118000, C544S127000, C544S333000, C514S234200, C514S256000
Reexamination Certificate
active
06797718
ABSTRACT:
FIELD
This invention relates to imidazopyridine compounds that have ether or thioether substitution at the 1-position, and that may contain additional functionality. The invention also provides pharmaceutical compositions containing these compounds and methods of inducing cytokine biosynthesis by administration of the compounds.
BACKGROUND
The first reliable report on the 1H-imidazo[4,5-c]quinoline ring system, Backman et al.,
J. Org. Chem.
15, 1278-1284 (1950) describes the synthesis of 1-(6-methoxy-8-quinolinyl)-2-methyl-1H-imidazo[4,5-c]quinoline for possible use as an antimalarial agent. Subsequently, syntheses of various substituted 1H-imidazo[4,5-c] quinolines were reported. For example, Jain et al.,
J. Med. Chem.
11, pp. 87-92 (1968), synthesized the compound 1-[2-(4-piperidyl)ethyl]-1H-imidazo[4,5-c]quinoline as a possible anticonvulsant and cardiovascular agent. Also, Baranov et al.,
Chem. Abs.
85, 94362 (1976), have reported several 2-oxoimidazo[4,5-c]quinolines, and Berenyi et al.,
J. Heterocyclic Chem.
18, 1537-1540 (1981), have reported certain 2-oxoimidazo[4,5-c]quinolines.
Certain 1H-imidazo[4,5-c]quinolin-4-amines and 1- and 2-substituted derivatives thereof were later found to be useful as antiviral agents, bronchodilators and immunomodulators. These are described in, inter alia, U.S. Pat. Nos. 4,689,338; 4,698,348; 4,929,624; 5,037,986; 5,268,376; 5,346,905; and 5,389,640, all of which are incorporated herein by reference.
Substituted 1H-imidazopyridine-4-amine compounds useful as immune response modifiers are described in U.S. Pat. Nos. 5,446,153; 5,494,916; 5,644,063; 6,525,064; 6,545,016; and 6,545,017. The compounds described in these patents do not have ether substitution at the 1-position. Certain 1H-imidazo[4,5-c]quinolin-4-amines that have amide, sulfonamide, and urea functionality at the 1-position are described in U.S. Pat. Nos. 6,331,539; 6451,810; and 6,541,485.
Despite these recent discoveries of compounds that are useful as immune response modifiers, there is a continuing need for compounds that have the ability to modulate the immune response, by induction of cytokine biosynthesis or other mechanisms.
SUMMARY
In one aspect, the invention provides imidazopyridine compounds that have ether substitution at the 1-position. These compounds have the general formula (Ia):
wherein X, W, and the various R variables are as defined herein. In other aspects, the invention provides pharmaceutical compositions containing the compounds and methods of using the compounds to achieve a therapeutic effect. Such effects include the induction of cytokine biosynthesis, the induction of interferon biosynthesis, treatment of viral conditions and treatment of neoplastic conditions. In other aspects, the invention additionally provides methods of making the compounds and intermediate compounds useful in their synthesis.
Many of the compounds of the invention have an ether linkage at the 1-position of the compounds. The compounds may include additional substitution that occurs after the initial ether linkage, such as aryl, heteroaryl, heterocyclyl, amido, sulfonamido, urea, and the like. An additional set of compounds provided by the invention contain a thioether linkage at the 1-position; these thioether compounds may also have additional substitution after the initial thioether linkage, including alkyl, aryl, heteroaryl, and heterocyclyl.
REFERENCES:
patent: 3314941 (1967-04-01), Littell et al.
patent: 4689338 (1987-08-01), Gerster
patent: 4698348 (1987-10-01), Gerster
patent: 4929624 (1990-05-01), Gerster et al.
patent: 4988815 (1991-01-01), Andre et al.
patent: 5037986 (1991-08-01), Gerster
patent: 5175296 (1992-12-01), Gerster
patent: 5238944 (1993-08-01), Wick et al.
patent: 5266575 (1993-11-01), Gerster
patent: 5268376 (1993-12-01), Gester
patent: 5346905 (1994-09-01), Gerster
patent: 5352784 (1994-10-01), Nikolaides et al.
patent: 5367076 (1994-11-01), Gerster
patent: 5389640 (1995-02-01), Gerster et al.
patent: 5395937 (1995-03-01), Nikolaides et al.
patent: 5446153 (1995-08-01), Lindstrom et al.
patent: 5482936 (1996-01-01), Lindstrom
patent: 5693811 (1997-12-01), Lindstrom
patent: 5741908 (1998-04-01), Gerster et al.
patent: 5756747 (1998-05-01), Gerster
patent: 5939090 (1999-08-01), Beaurline et al.
patent: 6039969 (2000-03-01), Tomai et al.
patent: 6069149 (2000-05-01), Nanba et al.
patent: 6083505 (2000-07-01), Miller et al.
patent: 6110929 (2000-08-01), Gerster et al.
patent: 6194425 (2001-02-01), Gerster et al.
patent: 6245776 (2001-06-01), Skwierczynski et al.
patent: 6331539 (2001-12-01), Crooks et al.
patent: 6376669 (2002-04-01), Rice et al.
patent: 6451810 (2002-09-01), Coleman et al.
patent: 6518265 (2003-02-01), Kato et al.
patent: 6525064 (2003-02-01), Dellaria et al.
patent: 6541485 (2003-04-01), Crooks et al.
patent: 6545016 (2003-04-01), Dellaria et al.
patent: 6545017 (2003-04-01), Dellaria et al.
patent: 6558951 (2003-05-01), Tomai et al.
patent: 6573273 (2003-06-01), Crooks et al.
patent: 2002/0055517 (2002-05-01), Smith
patent: 2002/0058674 (2002-05-01), Hedenstrom et al.
patent: 0 394 026 (1990-10-01), None
patent: 1 104 764 (2001-06-01), None
patent: 9-208584 (1997-08-01), None
patent: 9-255926 (1999-03-01), None
patent: 11-222432 (1999-08-01), None
patent: 2000-247884 (2000-09-01), None
patent: WO 01/74343 (2001-10-01), None
patent: WO 02/36592 (2002-05-01), None
patent: WO 02/46188 (2002-06-01), None
patent: WO 02/46189 (2002-06-01), None
patent: WO 02/46190 (2002-06-01), None
patent: WO 02/46191 (2002-06-01), None
patent: WO 02/46192 (2002-06-01), None
patent: WO 02/46193 (2002-06-01), None
patent: WO 02/46749 (2002-06-01), None
patent: WO 02/102377 (2002-12-01), None
patent: WO 03/020889 (2003-03-01), None
patent: WO 03/043572 (2003-05-01), None
patent: WO 03/045391 (2003-06-01), None
Wozniak, et al, “The Amination of 3-nitro-1, 5-naphthyridines by Liquid Ammonia/Potassium Permanganate1,2. A New and Convenient Amination Method.”,Journal of the Royal Netherlands Chemical Society, 102, pp 511-513, Dec. 12, 1983.
Brennan, et al, “Automated Bioassay of Interferons in Micro-test Plates”,Biotechniques, Jun./Jul., 78, 1983.
Testerman, et al., “Cytokine Induction by the Immunomodulators Imiquimod and S-27609”,Journal of Leukocyte Biology, vol. 58, pp. 365-372, Sep. 1995.
Bachman, et al, “Synthesis of Substituted Quinolylamines. Derivatives of 4-Amino-7-Chloroquinoline”,J. Org. Chem., 15, pp 1278-1284 (1950).
Jain, et al, “Chemical and Pharmacological Investigations of Some &ohgr;-Substituted Alkylamino-3-aminopyridines”,J. Med. Chem.., 11, pp 87-92 (1968).
Baranov, et al.,Chem. Abs.85, 94362, (1976).
Berényi, et al, “Ring Transformation of Condensed Dihydro-as-triazines”,J. Heterocyclic Chem., 18, pp 1537-1540 (1981).
Chollet, et al, “Development of a Topically Active Imiquimod Formulation”,Pharmaceutical Development and Technology, 4(1), pp 35-43 (1999).
Izumi, et al., “1H-Imidazo[4,5-c]quinoline Derivatives as Novel Potent TNF-&agr; Suppressors: Synthesis and Structure-Activity Relationship of 1-, 2- and 4-Substituted 1H-imidazo[4,5-c]pyridines”,Bioorganic&Medicinal Chemistry, 11, pp 2541-2550 (2003).
Dellaria Joseph F.
Dressel Luke T.
Heppner Philip D.
Jacobsen John R.
Lindstrom Kyle J.
3M Innovative Properties Company
Aulakh Charanjit S.
Ersfeld Dean A.
LandOfFree
Ether substituted imidazopyridines does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Ether substituted imidazopyridines, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Ether substituted imidazopyridines will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3242626